Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Double-blind, Active-controlled Study Evaluating the Safety and Immunogenicity of IVT PCV-25 in Healthy Infants Administered With the WHO Expanded Programme on Immunization 3+0 Vaccine Schedule

NCT06790290 is registered in ClinicalTrials.gov with Inventprise Inc. as lead sponsor.

NCT NCT06790290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06790290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Double-blind, Active-controlled Study Evaluating the Safety and Immunogenicity of IVT PCV-25 in Healthy Infants Administered With the WHO Expanded Programme on Immunization 3+0 Vaccine Schedule
Lead sponsor
Inventprise Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 27, 2025
Completion date
December 31, 2026
Enrollment
421 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease, invasive